NCT05296304 2026-02-04
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
Clinical Trials
9 trialsNCT04664829 2025-09-23
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
National Cancer Centre, Singapore
Phase 1 Completed
NCT03323658 2023-01-10
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01134341 2019-12-18
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01504490 2017-02-14
Phase I Study of CS-7017 and Bexarotene
Georgetown University
Phase 1 Terminated
NCT00316030 2016-06-08
Study of Bexarotene in Patients With Acute Myeloid Leukemia
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00127101 2015-04-21
An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01001143 2014-07-29
AML
Washington University School of Medicine
Phase 1 Completed
NCT00055991 2013-02-05
Bexarotene in Preventing Breast Cancer in Women at Genetic Risk
Baylor Breast Care Center
Phase 1 Completed